Answers are grounded in this paper and cite their sources.
These preclinical and clinical results support a role of NF-κB and IL-6 in the resistance to D in CRPC, and support the investigation of targeted therapies to enhance the antitumor activity of D in this patient population.
No takes yet. Share an insight, caveat, or question.
Codony‐Servat et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: